Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy

A Southwest Oncology group study

Amy D. Tiersten, James Moon, Harriet O. Smith, Sharon P. Wilczynski, William R. Robinson, Maurie Markman, David S Alberts

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: In vitro testing of the activity of chemotherapeutic agents has been suggested as 1 method to optimally select drugs for patients with ovarian cancer. There are limited prospectively obtained data examining the clinical utility of this approach. We sought to obtain a preliminary assessment of this strategy in a trial that examined the administration of neoadjuvant chemotherapy followed by surgical cytoreduction and intraperitoneal chemotherapy in women with advanced ovarian cancer. Methods: Women with stage III/IV epithelial ovarian carcinoma that presented with large-volume disease were treated with neoadjuvant intravenous paclitaxel and carboplatin for three 21-day cycles followed by cytoreductive surgery. If optimally debulked, patients received intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel for six 28-day cycles. Tumor cloning assay results (Oncotech) were correlated with progression-free survival. Results: Sixty-two patients (58 eligible) were registered from March 2001 to February 2006. Thirty-six eligible patients had interval debulking and 26 received postcytoreduction chemotherapy. Twenty-two patients had tumor cloning assay results available. The clinical features of this population were similar to those of the larger group of women who entered this study. There was no difference in progression-free survival between patients whose cancers were defined as 'resistant' or 'nonresistant' to either platinum or paclitaxel. Conclusions: While the small patient numbers in this trial do not permit definitive conclusions, these data fail to provide support for the argument that prospectively obtained in vitro data regarding platinum or paclitaxel resistance will be highly predictive of clinical outcome in advanced ovarian cancer.

Original languageEnglish (US)
Pages (from-to)395-399
Number of pages5
JournalOncology
Volume77
Issue number6
DOIs
StatePublished - Feb 2010

Fingerprint

Ovarian Neoplasms
Disease-Free Survival
Paclitaxel
Drug Therapy
Carboplatin
Platinum
Organism Cloning
Neoplasms
Carcinoma
Pharmaceutical Preparations
Population

Keywords

  • Carboplatin
  • Cytoreduction
  • Neoadjuvant chemotherapy
  • Ovarian cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy : A Southwest Oncology group study. / Tiersten, Amy D.; Moon, James; Smith, Harriet O.; Wilczynski, Sharon P.; Robinson, William R.; Markman, Maurie; Alberts, David S.

In: Oncology, Vol. 77, No. 6, 02.2010, p. 395-399.

Research output: Contribution to journalArticle

@article{254ba3aa3b0d43c98632c8b0fc63c932,
title = "Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: A Southwest Oncology group study",
abstract = "Purpose: In vitro testing of the activity of chemotherapeutic agents has been suggested as 1 method to optimally select drugs for patients with ovarian cancer. There are limited prospectively obtained data examining the clinical utility of this approach. We sought to obtain a preliminary assessment of this strategy in a trial that examined the administration of neoadjuvant chemotherapy followed by surgical cytoreduction and intraperitoneal chemotherapy in women with advanced ovarian cancer. Methods: Women with stage III/IV epithelial ovarian carcinoma that presented with large-volume disease were treated with neoadjuvant intravenous paclitaxel and carboplatin for three 21-day cycles followed by cytoreductive surgery. If optimally debulked, patients received intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel for six 28-day cycles. Tumor cloning assay results (Oncotech) were correlated with progression-free survival. Results: Sixty-two patients (58 eligible) were registered from March 2001 to February 2006. Thirty-six eligible patients had interval debulking and 26 received postcytoreduction chemotherapy. Twenty-two patients had tumor cloning assay results available. The clinical features of this population were similar to those of the larger group of women who entered this study. There was no difference in progression-free survival between patients whose cancers were defined as 'resistant' or 'nonresistant' to either platinum or paclitaxel. Conclusions: While the small patient numbers in this trial do not permit definitive conclusions, these data fail to provide support for the argument that prospectively obtained in vitro data regarding platinum or paclitaxel resistance will be highly predictive of clinical outcome in advanced ovarian cancer.",
keywords = "Carboplatin, Cytoreduction, Neoadjuvant chemotherapy, Ovarian cancer, Paclitaxel",
author = "Tiersten, {Amy D.} and James Moon and Smith, {Harriet O.} and Wilczynski, {Sharon P.} and Robinson, {William R.} and Maurie Markman and Alberts, {David S}",
year = "2010",
month = "2",
doi = "10.1159/000279386",
language = "English (US)",
volume = "77",
pages = "395--399",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy

T2 - A Southwest Oncology group study

AU - Tiersten, Amy D.

AU - Moon, James

AU - Smith, Harriet O.

AU - Wilczynski, Sharon P.

AU - Robinson, William R.

AU - Markman, Maurie

AU - Alberts, David S

PY - 2010/2

Y1 - 2010/2

N2 - Purpose: In vitro testing of the activity of chemotherapeutic agents has been suggested as 1 method to optimally select drugs for patients with ovarian cancer. There are limited prospectively obtained data examining the clinical utility of this approach. We sought to obtain a preliminary assessment of this strategy in a trial that examined the administration of neoadjuvant chemotherapy followed by surgical cytoreduction and intraperitoneal chemotherapy in women with advanced ovarian cancer. Methods: Women with stage III/IV epithelial ovarian carcinoma that presented with large-volume disease were treated with neoadjuvant intravenous paclitaxel and carboplatin for three 21-day cycles followed by cytoreductive surgery. If optimally debulked, patients received intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel for six 28-day cycles. Tumor cloning assay results (Oncotech) were correlated with progression-free survival. Results: Sixty-two patients (58 eligible) were registered from March 2001 to February 2006. Thirty-six eligible patients had interval debulking and 26 received postcytoreduction chemotherapy. Twenty-two patients had tumor cloning assay results available. The clinical features of this population were similar to those of the larger group of women who entered this study. There was no difference in progression-free survival between patients whose cancers were defined as 'resistant' or 'nonresistant' to either platinum or paclitaxel. Conclusions: While the small patient numbers in this trial do not permit definitive conclusions, these data fail to provide support for the argument that prospectively obtained in vitro data regarding platinum or paclitaxel resistance will be highly predictive of clinical outcome in advanced ovarian cancer.

AB - Purpose: In vitro testing of the activity of chemotherapeutic agents has been suggested as 1 method to optimally select drugs for patients with ovarian cancer. There are limited prospectively obtained data examining the clinical utility of this approach. We sought to obtain a preliminary assessment of this strategy in a trial that examined the administration of neoadjuvant chemotherapy followed by surgical cytoreduction and intraperitoneal chemotherapy in women with advanced ovarian cancer. Methods: Women with stage III/IV epithelial ovarian carcinoma that presented with large-volume disease were treated with neoadjuvant intravenous paclitaxel and carboplatin for three 21-day cycles followed by cytoreductive surgery. If optimally debulked, patients received intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel for six 28-day cycles. Tumor cloning assay results (Oncotech) were correlated with progression-free survival. Results: Sixty-two patients (58 eligible) were registered from March 2001 to February 2006. Thirty-six eligible patients had interval debulking and 26 received postcytoreduction chemotherapy. Twenty-two patients had tumor cloning assay results available. The clinical features of this population were similar to those of the larger group of women who entered this study. There was no difference in progression-free survival between patients whose cancers were defined as 'resistant' or 'nonresistant' to either platinum or paclitaxel. Conclusions: While the small patient numbers in this trial do not permit definitive conclusions, these data fail to provide support for the argument that prospectively obtained in vitro data regarding platinum or paclitaxel resistance will be highly predictive of clinical outcome in advanced ovarian cancer.

KW - Carboplatin

KW - Cytoreduction

KW - Neoadjuvant chemotherapy

KW - Ovarian cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=75549088386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75549088386&partnerID=8YFLogxK

U2 - 10.1159/000279386

DO - 10.1159/000279386

M3 - Article

VL - 77

SP - 395

EP - 399

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 6

ER -